Swainsonine is an indolizidine alkaloid. It is a potent Enzyme inhibitor of Golgi alpha-mannosidase II, an immunomodulator, and a potential chemotherapy drug.
Pharmacology
Swainsonine inhibits glycoside hydrolases, specifically those involved in
N-linked glycosylation. Disruption of Golgi alpha-mannosidase II with swainsonine induces hybrid-type
glycans. These glycans have a Man5GlcNAc2 core with processing on the 3-arm that resembles so-called complex-type glycans.
The pharmacological properties of this product have not been fully investigated.
Sources
Some plants, such as
Oxytropis ochrocephala, do not produce the toxic compound themselves, but are host to endophytic fungi which produces swainsonine, such as
Alternaria oxytropis.
| + Fungal Sources |
|
Undifilum oxytropis |
Metarhizium anisopliae |
| + Plant sources |
|
Swainsona canescens, Astragalus earlei, A. mollissimus, A. pubentissimus, A. lentiginosis, A. wootoni, A. nothoxys, A. tephrodes, A. humistratus |
Jacquemontia corymbulosa, Ipomoea verbascoidea, I. subincana, I. megapotamica, Ipomoea rosea, Ipomoea carnea, I. sericophylla, Ipomoea riedelii |
Biosynthesis
The biosynthesis of swainsonine has been investigated in the fungus
Rhizoctonia leguminicola, and it initially involves the conversion of
lysine into
pipecolic acid. The
pyrrolidine ring is then formed via retention of the carbon atom of the pipecolate's
Carboxylic acid group, as well as the coupling of two more carbon atoms from either
acetate or
malonate to form a pipecolylacetate. The retention of the carboxyl carbon is striking, since it is normally lost in the biosynthesis of most other alkaloids.
[ ]
The resulting oxoindolizidine is then reduced to (1 R,8a S)- 1-hydroxyindolizidine, which is subsequently at the C2 carbon atom to yield 1,2-dihydroxyindolizidine. Finally, an 8-hydroxyl group is introduced through epimerization at C-8a to yield swainsonine. Schneider et al. have suggested that oxidation occurs at C-8a to give an iminium. Reduction from the β face would then yield the R configuration of swainsonine, as opposed to the S configuration of slaframine, another indolizidine alkaloid whose biosynthesis is similar to that of swainsonine during the first half of the pathway and also shown above alongside that of swainsonine. The instance at which oxidation and reduction occur with regard to the introduction of the hydroxyl groups at the C2 and C8 positions is still under investigation.
The biosynthetic pathway of swainsonine has also been investigated in the Diablo locoweed ( Astragalus oxyphysus). Through detection of (1,8a- trans)-1-hydroxyindolizidine and (1,8a- trans-1,2- cis)-1,2-dihydroxyindolizidine—two precursors of swainsonine in the fungus pathway—in the shoots of the plant, Harris et al. proposed that the biosynthetic pathway of swainsonine in the locoweed is nearly identical to that of the fungus.
Synthesis
Despite the small size of swaisonine, the synthesis of this molecule and its analogues is quite challenging due to the presence of four chiral centers. In most cases, synthesis implies the use of sugars, chiral aminoacids as starting compounds, or chiral catalysts to induce chirality.The swainsonine synthesis was systemazed by three common precursors: 8-oxy-hexahydroindolizines,
N-protected-3-oxy-2-substituted-piperidines and 2-substituted-pyrrolidine-3,4-protected-diols.
Livestock losses
Because chronic intoxication with swainsonine causes a variety of neurological disorders in
livestock,
these plant species are known collectively as
. Other effects of intoxication include reduced appetite and consequent reduced growth in young animals and loss of weight in adults, and cessation of reproduction (loss of libido, loss of fertility, and abortion).
Potential uses
Swainsonine has a potential for treating cancers such as
glioma and
stomach cancer.
However, a phase II
clinical trial of GD0039 (a hydrochloride salt of swainsonine) in 17 patients with
kidney cancer was discouraging.
Swainsonine's activity against tumors is attributed to its stimulation of
.
Swainsonine also has potential uses as an adjuvant for anti-cancer drugs and other therapies in use. In mice, swainsonine reduces the toxicity of doxorubicin, suggesting that swainsonine might enable use of higher doses of doxorubicin.
Molecular mechanism
The inhibitory effect of swainsonine on Golgi Mannosidase II (GMII) was proposed to be due to its ability to bind in the GMII binding pocket in a similar fashion as the natural GMII substrate in its transition state.
Later, it was shown that the binding pattern of the swainsonine molecule resembles that of the Michaelis complex of mannose and only the protonated, charge positive swainsonine molecule binds similarly to the substrate in its transition state.
The actual state in which swainsonine binds in the mannosidase remains undetermined and is most likely dependent on the pH at which the enzyme operates.
[
]
See also
